Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
ERJ Open Research|December 2, 2020
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic coughDavid R Muccino, Alyn H Morice, Surinder S Birring, et al.
American Journal of Respiratory and Critical Care Medicine|March 5, 2025
Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE)Jaclyn A Smith, Surinder S Birring, Michael S Blaiss, et al.
Respiratory Research|April 11, 2023
The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trialChristian Friedrich, Klaus Francke, Surinder S Birring, et al.
Lung|June 1, 2023
Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI StudyPeter V Dicpinigaitis, Alyn H Morice, Jaclyn A Smith, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 1, 2016
Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutationGemma L Zeybel, Jeffrey P Pearson, Amaran Krishnan, et al.
The Lancet. Respiratory Medicine|February 29, 2020
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trialJaclyn A Smith, Michael M Kitt, Alyn H Morice, et al.
The European Respiratory Journal|August 22, 2014
Expert opinion on the cough hypersensitivity syndrome in respiratory medicineAlyn H Morice, Eva Millqvist, Maria G Belvisi, et al.
ERJ Open Research|June 24, 2026
Measuring the effect of azithromycin in chronic respiratory disease using continuous cough monitoring: an open-label exploratory trialDominic L Sykes, Kayleigh Brindle, Syed Kazmi, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 15, 2022
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic coughPeter V Dicpinigaitis, Surinder S Birring, Michael Blaiss, et al.
Lung|July 27, 2022
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined SubgroupsJaclyn A Smith, Surinder S Birring, Peter V Dicpinigaitis, et al.
Pageof 16